Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
--------
Question: The U.S. Food and Drug Administration questioned the differences in size and formulation of the patch used in trials and the to-be-marketed patch. The generic drugs maker, which received a “complete response letter” from the FDA, said it planned to work closely with the agency to address the questions. Such letters typically lay out FDA concerns that need to be addressed before a treatment is approved. Actavis’ contraceptive skin patch is designed to provide continuous delivery of the hormone norethindrone, a type of progestin, during a once-weekly, seven-day dosing regimen. Progestin, the synthetic form of female sex hormone progestogen, inhibits ovulation and thickens the layer of mucus at the cervix so sperm cannot enter the uterus. The treatment will compete with Johnson and Johnson’s Ortho Evra, an estrogen/progestin combination contraceptive patch. Estrogen is another female sex hormone. A progestin-only patch can be safer than combination patches as high levels of estrogen are often linked to blood clotting disorders and an increased risk of cancer. The company also filed on Tuesday an application to market the generic version of Merck & Co Inc’s NuvaRing, a estrogen/progestin combination hormonal contraceptive vaginal ring. Actavis said it may be the first applicant to file the application, which, if approved may entitle it to 180 days of generic market exclusivity. Shares of Dublin, Ireland-based Actavis were down 0.6 percent at $165.16 in early trading on the New York Stock Exchange on Tuesday.

Answer: FDA rejects Actavis' contraceptive patch, seeks more data.


Question: Luke Miels, who joined GSK in September 2017 after a contract dispute with his former employer AstraZeneca, said picking the most promising projects and developing them quickly now takes precedence over spreading the risk of failure. “In the past, 10 programs were chosen, a budget for eight was allocated. Usually what happened was that time was the trade off that was made,” he said in an interview. “Now what we do is we pick five or six programs, and concentrate investment there.”   GSK, like rivals, was in the habit of testing new drugs first on patients who had run out of other treatment options. If successful, it would try patients at an earlier stage of their disease, replacing older, established treatments. In today’s market, where rivals in the United States and China catch up fast if a new class of drug shows promise, GSK has to run costly drug tests on humans in several settings at the same time, even if it means dropping other drug candidates. “Rather than do things sequentially, you do them in parallel, or as close to parallel as possible,” Miels said. GSK, which is battling to return to profit growth, has taken this approach for instance with an experimental drug that for now goes by the code name of GSK’916 against multiple myeloma, a common and incurable type of blood cancer. Likewise, GSK doubled down on its quest to bring a drug known as GSK’165 to market as a rheumatoid arthritis treatment, even after initial results in a mid-stage drug trial did not show a clear enough reading. “This drug has very interesting effects on pain. That could potentially reduce the use of opioids and pain meds,” Miels said. More trials will be run to make the pain argument more clearly, he added. GSK expects a decline of 5%-9% in adjusted earnings per share this year, excluding exchange rate moves, as it suffers from generic competition to its inhalable lung drug Advair and pressure from rival Gilead in HIV treatments. Miels said a tougher stance on drug prices by U.S. lawmakers and medical insurers was one of the reasons for the need for speed in bringing drugs to market - to try to remain ahead of competitors for as long as possible. At the same time, rapid growth in the Chinese market was spurring a more sophisticated healthcare system there, with local biotech groups quick to catch up with Western pioneers in drug development, producing similar drugs for their home market.

Answer: GSK pharma head flags need for speed in high-pressure drug market.


Question: The WHO’s Kate O’Brien put the blame on weak health systems and misinformation about vaccines, and called on social media outlets and communities to make sure information about preventing the highly contagious disease was accurate. “We are backsliding, we are on the wrong track,” O’Brien, director of WHO’s department of immunization, vaccines and biologicals, told a news briefing. “We have a worrying trend that all regions are experiencing an increase in measles except for the region of the Americas, which has seen a small decline.”   Nearly three times as many cases were reported from January to July this year than in the same period in 2018, the WHO said. Nearly 365,000 cases have been reported globally this year,  the highest figure since 2006, it said, noting that they represent only a fraction of the 6.7 million suspected cases. Measles caused an estimated 109,000 deaths in 2017, its most recent figures show. The biggest outbreaks are raging in the Democratic Republic of Congo (155,460 cases), Madagascar (127,454) and Ukraine (54,246), it said. Europe has also lost ground, with four countries stripped of their “measles-free” status in 2018 - Albania, Czech Republic, Greece and Britain, it said. The WHO figures did not include a specific breakdown of numbers for the Americas region. The United States has recorded 1,215 measles cases across 30 states in its worst outbreak since 1992, federal health officials said on Monday. Health experts say the virus has spread among school-age children whose parents declined to give them the measles-mumps-rubella vaccine, which confers immunity to the disease. Trust in vaccines - among the world’s most effective and widely used medical products - is highest in poorer countries but weaker in wealthier ones where scepticism has allowed outbreaks of diseases such as measles to persist, a global study found in June. “We do see misinformation as an increasing threat,” O’Brien said. “We are calling on social media providers, communities, leaders, people who speak out, to be sure you are communicating accurate, valid, scientifically credible information.”  In the 53 countries of Europe, 90,000 measles cases were recorded in the first half of this year, already more than that for all of 2018, said Siddhartha Datta, from the WHO’s regional office for Europe. Ukraine, which accounts for more than half of the cases, is implementing a robust response, he said. “The ministry of health is doing targeted immunization campaigns ... They are also doing school-based vaccination, high-risk vaccination of military recruits and health care workers.”  (This story was refiled to fix typo in first paragraph.)

Answer:
Global measles cases three times higher than last year: WHO.